Tempest Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2011 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Tempest Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2011 to Q2 2024.
  • Tempest Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $1.32M, a 200% increase year-over-year.
  • Tempest Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $4.3M, a 145% increase year-over-year.
  • Tempest Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2.55M, a 63.1% increase from 2022.
  • Tempest Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1.56M, a 41.3% increase from 2021.
  • Tempest Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $1.11M, a 144% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $4.3M $1.32M +$880K +200% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $3.42M $1.32M +$872K +196% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $2.55M $1.1M +$669K +156% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-19
Q3 2023 $1.88M $563K +$125K +28.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $1.75M $440K +$73K +19.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $1.68M $446K +$118K +36% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $1.56M $428K +$150K +54% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-19
Q3 2022 $1.41M $438K +$142K +48% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $1.27M $367K -$44K -10.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $1.31M $328K +$208K +173% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $1.11M $278K +$1.22M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 -$118K $296K +$205K +225% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$323K $411K +$184K +81.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$507K $120K -$960K -88.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 $453K -$945K -$2.13M -180% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-29
Q3 2020 $2.59M $91K -$1.11M -92.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $3.69M $227K -$767K -77.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $4.46M $1.08M +$141K +15% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $4.32M $1.19M +$520K +77.8% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-29
Q3 2019 $3.8M $1.2M +$773K +183% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $3.02M $994K +$835K +525% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $2.19M $939K +$762K +431% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 $1.43M $668K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 $423K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 $159K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-12
Q1 2018 $177K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q3 2013 $200K -$100K -33.3% Jul 1, 2013 Sep 30, 2013 10-Q 2013-11-13
Q3 2012 $300K +$270K +900% Jul 1, 2012 Sep 30, 2012 10-Q 2012-11-13
Q2 2012 $299K Apr 1, 2012 Jun 30, 2012 10-Q 2012-08-14
Q3 2011 $30K Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.